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Ribavirin Treatment of Murine Coxsackievirus B, Myocarditis With 
Analyses of Lymphocyte Subsets 
CHIHARU KISHIMOTO, MD, PHD, CLYDE S. CRUMPACKER, MD, 
WALTER H. ABELMANN, MD, FACC 
The efficacy of the synthetic nuckoside ribavirin in Ihe 
therapy of experimental myocardilis caused by cowpckie. 
virus B, and Its effects on peripheral and spknk lympho- 
cyte subsets were investigated. Two week old male C$IHRle 
mice were inoculated wilh coworkievirus B,, Rlbavirln was 
administered subcutaneously on days 0 Lo 15 (experiment I) 
and on days 4 Lo 15 (experiment II) in a dose of 200 
(experiment I: Group 2, n = 10; experiment II: Group 5, n 
= 10) or 400 q/kg per day (experiment I: Group 3, n = 10; 
experiment II: Group 6, n = IO). Control mice (experiment 
I: Group 1, o = 15; experiment II: Group 4, n = 14) 
received an injection of saline soiulion. 
In experiment I, mice Wated wilh ribavirin survived 
significantly longer than did control mice (p = 0.005, 
Group 1 versus Group 2; p = 0.001, Group 1 versus Gruup 
3). In experiment II, the survival r&e on day 15 in 
ribavirin-treated mice was high compared with that in 
control mice (Group 4 = 14.3%, Group 5 = 20%, Group 6 
= 50%). Myocsrdial viral tilers on day8 5 lo 8 were 
significantly lower in ribavirfn.lreated mice of both exper. 
iments lban in control mice. Histologic examination showed 
extensive mjocrrdial necrosis and cellular inlillralion in 
untreated groups; there WBS less infiltration in Group 3 
ip < 0.001) and Group 6 (p < 0.09, less severe necrosis in 
- 
With the use of endomyocardial biopsy, myocarditis has 
become recognized more widely (I-3). Viral infections com- 
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Group 2 and 3 (p < 0.001) and Group 6 (p < 0.01) and less 
calcilkatlcm in Groups 2 and 3 (p < 0.001) and Groups 5 
(p C 0.05) and 6 (p c O.OOl), 
For analysis of lymphocyte subsets of the peripheral 
blood and spleen, six addllkmal mice from ench of Ihe five 
groups (Groups 1,2,3,5 and 6) were kllkd on days 6 to 10. 
The percentages of B cellr, Thy t.2’ (pan T), Lyt I+, W+ 
(precursor of other T cell subseta), Lyt I+, 23- (helper/ 
inducer T), Lyt l-, 23+ (suppressor/cytotoxic T and WT4+ 
(activated helper T) subsets were caktdated. In Group 1 
(Infected, nontreated), the pe~ofTky 1.2+, Lyl l+, 
W+, Lyt I+, 23- and L3T4* subsels In the peripheral 
bload and q&en wm decd *aWly caqued 
with (hose of uninfected mkt. However, in the peripheral 
bloud uf riIwir&btre&d mice, Ik decreae uf percentages 
of Thy 1.2+ and L3T4+ s&se& was signiikan~ly less severe 
Lhen thet in untreated mke (Group 1). 
Thus, early adminlstralion of ribavirfn effcrtively khib- 
ikd myocrrdinl couackkvirw B, replkatiom aitd reduced 
myorardial dq during Ilte aWe viral infection, with 
improvement of the depletion of pan T and helper T subsels 
caused by coxsackievirus B, in Ihb anlltlrl modei. 
(,I Am Cdl Cm&l t!M8:12:1334A~) 
manly initiate the disease, although the suspected antigen is 
rarely isolated from patients with myocardilis (4-7). Current 
therapy for viral myocarditis is symptomatic and supportive 
because our understanding of the pathogenesis of myocar- 
ditis in humans is limited. The efficacy of immunosuppres- 
sive therapy for viral myocarditis has been controversial as 
indicated by both clinical (8.9) and experimentul studies 
(lfLl3). 
Ribavirin is a synthetic nucleoside, structurally related to 
inosine and guanosine, and has been shown (14) to have a 
remarkably broad spectrum of antiviral activity in laboratory 
systems. It has been reported from our laboratory (IS) that 
ribavirin has antiviral and protective activities against ence- 
phalomyocarditis viral myocarditis in DBAQ mice. How- 
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ever, antiviral and protective activities of ribavirin r;gainst five 1 week old mice. Ribavirin was administered subcuta- 
coxsackievirus B, infection have not been investigated. neousiy daily beginning immediately (experiment 1) or on the 
Coxsackieviruses are established as the predominant 4th day (experiment II) after virus inoculation until day 15. at 
cause of viral myocarditis in humans (4+6.7). In this study, a dose of 200 (Groups 2 and 5. each n = i0) or 400 mg/kg per 
we used an immunofluoresccnce technique (16) to investi- day (Groups 3 and 6, each n = IO). Control mice (Group I. 
gate the effects of ribavirin on murine cexsackievirus B1 n = IS; Group 4. n = 14) received injections of saline 
myocarditis as well as the kinetics of lymphocyte subsets in solution. In addition. three noninfected mice received 400 
the peripheral blood and spleen in mice with or without mgikg per day of ribavirin only on days 0 to 15, and they 
ribavirin treatment. served as the drug-treattd noninfected control group. Mice 
were observed daily and, when they were found dead. 
Methods 
complete necropsy was performed. Surviving mice were 
killed on day 15. 
Virus. Coxsackievirus B, (Nancy strain) was used. Viral Viral liters dheark The heart was removed aseptically. 
stock was stored at -7O’C until it was diluted for use. Viral weighed and homogenized in 2 ml of Eagle’s minimal essen- 
titers were determined by plaque formation on VERO-81 rial medium. After ccntrifugation at I SO0 gfor I5 min at 4°C. 
(kidney of African green monkey) cell monolayers. Cells the supematant was inoculated into VERO-81 cell monolay- 
were suspended al a concentration of I x @‘/ml in Eagle’s ers :md plaque assays were performed. 
minimal essential medium with 3% fetal calf serum plus 100 Pathologic stedy. The hearts were fixed in IO% formAn 
&ml of penicillin and streptomycin in six-well plastic plates solulion. embedded in paraffin and stained with hematoxy- 
and were allowed to grow for t days at 37°C in 5% carbon lin-eosin. Cellular infiltration. myocardial cell necrosis and 
dioxide. calcification were scored for severity. without knowledge of 
Volumes (0.1 ml) of decimal dilutions ot virus were other data. on a scale of I + to Jt: 0 indicated no lesions or 
adsorbed in VERO-81 cell monolayers for 60 min at 37°C’ in questionable lesions. It described a limited focal distribu- 
5% carbon dioxide. After adsorption. the celis were overlaid lion of myocardinl lesions. 4t described the presence of 
with 3 ml of medium containing 3% feral calf serum and I% multiple lesions over the entire heart whereas scores of 2+ 
methyl cellulose. After 2 days of incubation at 37°C in a and ?+ were used to describe intermediate severity. 
humidified atmosphere containing 5% carbon dioxide, cells Analysis of lymphocyte subsets. Virus inoculation and 
were fixed with acetic acid and methanol (at a ratio of t:3) ribavirin treatment of mice were the same as in experiments 
and stained with crystal violet (1%): plaques were counted I and II (Groups I, 2, 3. 5 and 6). For the analysis of 
with sn inverted microscope. lymphocyte subsets of the peripheral blood and spleen, six 
Ribsvirin se&ivily pssoys in vi& The antiviral drug additional mice from each of the five groups were killed on 
ribavirin (Virazole: I-beta-D-ribofuranosyI_i,~,J,-triazole-3- days 6 to IO. Two week old noninfected mice fn = 31, 
carhoxamide) was supplied by Viralek. A sterile solurion of noninfected age-matched mice for the study (n = 6) and the 
1,OMl &ml of ribavirin in distilled water was prepared. drug-treated noninfected mice (n = 3) were prepared, and 
Antiviral activity was assayed by a plaque-reduction lymphocyte subsets in these groups were also examined. 
method. Confluent monolayers of VERO-81 cells in six-weli Staining methods were similar to those described previously 
plastic plates were treated with medium containing various 1161. The spleen was minced gently with a sterile stainless 
concentrations of ribavirin (0, I. 10. 100 or ~800 &ml). steel mesh. After mincing, rhe cell suspension was rapidly 
Four hours later. cells were wsshed three times with phos- pipcned with a Pasteur pipette into 20 to 25 ml of Hank’s 
phate-buffered saline soMon and then inoctltated with IO0 balanced sd!l solution and centrifuged at 1,500 g for 5 min. 
plaque-forming units of the virus. The cells and the peripheral blood collected in heparin were 
After 2 days of incubation at 37°C cells were fixed with washed twice with Hank’s balanced salt solution. The red 
acetic acid-methanol. and stained with crystal violet and blood ceils in the peripheral blood were lysed by hypotonic 
plaques were counted. Plaque formation was expressed as shock. The lymphocyte fractions of these samples were 
percent of plaques of control mice. The drug concentration obtained by Ficotl gradient centrifugation. The lymphocytes 
required to reducr: the number of plaques by 50% from the were counted in it standard hemocytometer. The cells were 
number of conlrol wells (the median inhibitory dose) was finally suspended at a concentration of I x IO6 cells/ml in 
calculated from the graph relating plaque number and drug RPMI-1440 medium with 2.5% fetal calf serum and 0.2% 
concentration on a semi-log plot (linear regression) (171. sodium azide. 
WWS imrmtsth~~ and treatment of micez experiments I and B cells were determined by staining with Auorescein 
IL Two week old male CIK/He mice (Jackson Labor&tory) isothiocyanate-labeled rabbit antimouse immunogtobulin 
were inoculated intrdperitoneally with 0.1 ml of coxsacki- (Miles-Scientific). T cells were stained by using monoclonal 
virus BJ al a concentration of 3 x llv plaque-forming units/ rdr anti-Thy 1.2 (Becron-Dickinson). rat anti-L3T4 (Becton- 
ml. One mother mouse was supplied for the maintenance of Dickinson). raf anti-Lyt I (Becton-Dickinson) and rat anti- 
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Lyt 2 (Becton-Dickinson) as the first layer of antibodies and 
fluorescein isothiocyanate-labeled rabbit antimouse immu- 
noglobulin (Ig) as the second. 
Fluorescein isothiocyanate-labeled rabbit antimouse Ig 
was diluted lo-fold and rat monoclonal antibodies 5-fold. 
The cells were centrifuged at 1,SOO g for 3 min. After 
centrifugation, the cell pellet was suspended in 100 i of 
RPM&1640 medium with 2.5% fetal calf serum and 0.2% 
sodium azide or the first layer of antibodies. After incubation 
for 30 min at 4”C, the cells were washed three times and 
suspended in 100 ~1 of the second layer of antibodies. The 
cells were washed twice after 30 min of incubation at 4°C and 
suspended in 0.5 ml of RPMI-1640 medium with 2.5% fetal 
calf serum and 0.2% sodium azide. 
Preparations of these cells were observed under a fruo- 
resccnce microscope. The percent of positive fluorescent 
cells in each specimen was determined by the examination of 
at least 100 cells, The percent of T cell subsets was obtained 
by subtracting the percent of B cells from those obtained 
after staining with each monoclonal rat antibody and fluo- 
rescein isothiocyanate-labeled rabbit antimouse immuno- 
globulin, 
Calculations are as follows on the assumption that all T 
cells are positive for Thy 1.2 and bear either Lyt I or Lyt 2 
(18): 
Thy l.2 positive = (Lyt 1+,23+) t (Lyt 1+,23-j t (Lyt l-,23+) 
Lyr I posilive = (Lyt 1+,23+) + (Lyt t+,23-) 
Lyr 2 positive = (Lyt 1+,23*) t (Lyt i-,23+) 
Interpretalions (18). Thy I .2+ = total T cell population. 
Lyt I+,23 = precursor of the other T cell subsets (imma- 
ture T cell population). Lyt 1”,23- = helper/inducer T cell 
and effecters of delayed type hypersensitivity. Lyt l-,23+ = 
suppressorlcytotcvic T cell. L3T4+ = activated (antigen- 
stimulated) helper T cell. 
Statistics. Kaplan-Meier plots (19) were made of the 
survival data, and differences between the control and 
treatment survival curves were evaluated by the Mantel-Cox 
log-rank lest (20). The Kruskal-Wallis test (21) was used to 
evaluate the difference of histologic grading. Viral titers of 
the heart and percentages of the lymphocyte subsets were 
examined by an analysis of variance for multiple sample 
comparison (21). 
Results 
Antiviral activity In vitro. The percent plaque formation 
was 107 f 13% at a ribavirin concentration of t &ml, 54 2 
9% at 10 &ml, 13 + 15% at 100 &ml and 0% at 1.000 d 
ml (each II = 5). Linear regression analysis showed a good 
negative correlation of y = 97.8 - 36.2 log,,x (r = -0.948, 
p < 0.001) between plaque-forming units and logarithms of 
drug concentrations. Thus, the dose of ribavirin inhibiting 
50% of plaques was 21 &ml. 
PsO.005 Grpl vs. Grpi? 
0 




Figure 1. Effect of ribavirin (RB) on survival of C,H/He mice 
infected with coxsackievirus B, (CB3) in experiment I. Both riba- 
virinetreated Groups 2 and 3 survived significantly longer than 
control Group I. 
MortaMy. In experiment I (Fig. 11, all 15 control mice 
(Group 1) died between days 3 and 11. All treated groups 
survived significantly longer (p = 0.005, Group 1 versus 
Group 2; p = 0.001, Group 1 versus Group 3). In experiment 
II (Fig. 2), no mice in Groups 5 and 6 died before day 6, but 
3 of 14 mice in Group 4 (control) died before day 6. There 
were no significant differences in survival among these three 
groups. The percent surviving on day 15 was as follows: 
14.3% (2 of 14) in Group 4,20% (2 of IO) in Group 5 and 5046 
(5 of 10) in Group 6. None of the three mice in the 
drug-treated noninfected control poup died. 
Myocartull viral titer (Table 1). Myocardial viral titers 
were determined for mice that had died on days 5 to 8. In 
Flgurr 2. Effect of ribavirin (RB) on survival of CSHMe mice 
infected with coxsackicvirus B, (CB3) in experiment II. The percent 
surviving on day 15 in ribavirin-treated Groups 6 and 5 appears high 
compared with thet of conlrol Group 4. The differences, however, 
were not significant. 
tt 
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Tabk 1. Effect of Ribavirin on Coxsackievirtts B, Replication in the Heart (days 5 to 8) 
Dose of 
Ftibavirin Myacardial Vral Titer 
Gmup b-&g No. of (plaque-formmg U/g tissue) 
No. per day) Mice (mean ? SD) p Value 
I None 13 6.9 f 9.4 x Id 
2 200 7 3.3 ? 6.3 x IO’ 
I 
cod (NS) 
3 400 7’11) 9.0 -t IS.0 x Id (3.9 x Id) NS (NS) 
4 None 9 6.0 + 1.5 x Id - ‘co.05 - 
5 ZOO 8 1.8 5 3.5 x Id - - I co.01 
six aduitional mice killed on days 5 and 6 in another experiment, in an effort to attempt stalistical 
analysis. 
Group 3, six additional mice killed on days 5 and 6 were 
included because of the attempt to perform statistical anal- 
ysis. The mean myocardial viral titer of the 13 control mice 
in experiment I was 6.9 x 16 plaque-forming units/g. Those 
of the ribavirin-treated groups were 3.3 x IO’ in Group 2 (n 
= 7, p < 0.05) and 9.0 x Id in Group 3 (n = 7, p < 0.05). 
Those in experiment 11 were 6.0 x I6 in Group 4 (n = 9). I .8 
X 16 in Group 5 (n = B, p C 0.05) and 7. I x IO4 in Group 6 
(n = 5, p < 0.01). 
Hi&b@ Wings (T&k 2, Fig. 3). Cellular infiltration 
was significantly less severe in Groups 3 and 6 than in each 
control group, and myocardial necrosis was significantly less 
severe in Groups 2. 3 and 6 than in each control group. 
Myocardial calcification was significantly less severe in 
groups 2,3, 5 and 6 compared with each control group. 
Periphera! a& spkair lymphocyte subsets (Table 3). The 
percent of survival on day 6 after coxsackievirus 8, virus 
infection in this experiment was 70% (I4 of 20 mice) in the 
control group (Grc?up IL 100% (IO of 10) in Group 2, !W% 
(IO of IO) in Group :I, BO% IB of IO) in Group 5 and 90% (9 of 
IO) in Group 6. In rach subset there were no deaths and no 
significant changes In the peripheral blood or spleen among 
T&k 2. Effect of Ribavirin on Cnrdiac Histopathology 
Experiment I 
Gmup I Group 2 Group 3 
(n = IS) bt = I01 (n = IO) 
Group 4 
In = 14) 
Experiment II 
Gmup 5 
(n = IO) 
Grvup 6 
(n = I01 
Intiltft+tion 
0 0 4 0 0 0 
I+ 5 6 
2s 2 0 0 I 2 2 
3+ 6 4 0 7 3 2 
4+ 6 I 0 2 0 0 
p valltc* NS ~0.001 NS < 0.05 
6 0 0 
1-h 2 0 4 0 
2+ 0 2 6 2 
3t 4 3 0 7 4 2 
4+ 6 0 0 4 0 0 
p Vtduc’ co.01 <O.Ol NS qo.01 
Cakification 
0 2 0 0 6 
I+ 0 0 4 0 0 I 
2t I 1 I 2 6 I 
3+ 8 2 0 1 4 2 
4+ 4 I 0 7 4 ? 
p Value’ <0.00I <O.OoI co.05 ~O.cntl 
‘Cumparcd with control mice (Group I or 41. Ribavtrin was given m the fdlowingdoses (mdkg per day): Group 
I. now Gmup 2.200: Group 3.400: Gmup 4. MIIE Group 5. ?Do: Group 6.400. 
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the 2 week old noninfected group, noninfected age-matched 
group and drug-treated noninfected group. 
In the course of coxsackievirus 8, viral infection, the 
percent of T cells and subsets, except the Lyt I-, 23’ 
subset, was greatly decreased in the peripheral blood and 
spleen compared with the values in non‘infected mice. B cells 
in the peripheral blood and spleen, however. did not change 
significantly in the acute stage. Thus, in the acute stage of 
coxsackievirus B, infection, decreases in the percent of Thy 
Figure 3. Etrect of rib&in on cardiac histopatbology. A. Extensive 
myocardial necrosis and cellular infiltration are seen in an untreated 
mouse. B, In contrast, myocardial necrosis and cellular infiltration 
are minimal in a treated mouse. Original magnification xX& 
reduced by 25%. 
1.2+, Lyt I+ .23+,Lvt I +.23- and iJT4’ subsets were 
demonstrated. The decrease in the percentages of these four 
subsets in the peripheral blood of ribavirin-treated mice was 
IACC Vol. It, No. 5 KISHIMOTO ET AL. 1339 
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Noninfected’ group I I Group 2 Group 3 Group 5 Group 6 
(n = 61 (n = 6) 01 = 61 (II = 6) In = 6) (n = 6) 
Peripheral blood (9) 
6 Cells 22.1 -c 4.3 24.2 z 4.8 31.1 2 14x 24.8 * I?.0 23.7 5 7.9 26.5 2 6.6 
Thy 1.z+ 58.7 2 9.?t 24.4 2 13.4 41.5 2 11.7: 49.3 2 5.7f 45.8 2 22.39 46.7 5 II.39 
Lyt 1+,23+ 34.2 t 4.3, 13.2 -c- 8.1 !!.I 2 19.0 3U.8 + 13.1s 27.5 ? IS.34 22.5 * 7.3 
Lyt 1+,23- 21.2 c 6*3+ 6.7 r 4.g 13 5 2 15.5 14.2 ? 8.2 13.4 : 13.7 18.7 2 8.2 
Lyt i-. 23’ 3.3 2 2.7 4.5 2 4.6 6.6 2 5.2 4.3 t 4.0 4.9 2 5.2 5.5 * 3.3 
L3T4’ 4U.7 * 8.0+ 14.8 * 7.1 ‘6.7 2 Il.79 36.5 c 8.3+ 9.9 * I4.5§ 27.2 2 IO.O§ 
TLC(xl06) I.1 ? 0.6 I.4 2 0.5 I.4 c_ 0.4 I.4 * 0.7 1.3 2 0.s I.? 2 u.5 
Spleen (%) 
El cells 45 3 2 7.5 JO.0 * 7.8 42.0 2 I? I 43 J + 7.9 44.6 ? 13.5 44.6 + 7.9 
Thy l,2’ 43.0 5 4.7t 24.1 2 9.1 31.6? II8 19.1 2 I!.1 28.0 ? 7.0 27.0 5 5.3 
Lyt 1’,23+ 26.2 f 7.65 12.8 * 5.4 lo.0 ? IO.6 2o.u ? IO.6 16.8 2 8.3 18.9 5 6.1 
Lyt l+.23- 13.5 f 5.7t 7.9 + 6.7 16.3 + 13.3 6.5 ? 2.3 8.6 -c 5.5 6.9 ? 3.4 
Lyt l-,23’ 3.3 r 2.9 3.5 2 I.9 3.0 * 2.6 2.6 2 3.3 2.9 ? 3.9 3.1 * 3.8 
L3T4+ 27.9 ? 8.9f 16.g ? 7.3 27.0 f 7 I !I 0 ? 6.0 19.4 * 8.3 19.2 + 8.4 
TLC lx IO’) 3.0 -r 0.s I.9 ? U.7 3.1 ? 0.7 ? 9 ? 0.6 2.9 2 0.6 2.8 2 0.7 
‘Obtained from noninfected age-matched C,HIHe mice for the study and compared wrh thlr group: there bell: no significant chunges in each subset and !otal 
lymphocyte counts of Be periphe~l blood or the spleen in the ! week old noninfected group dad the nbauirin-Ire&d noninfected group: fp < 0.001 vs. control 
Gmup I): $p < 0.01: 9p < 0.05. P8 = peripheral blood: SP = rpleen: TLC = IOIJI lymphocyte cwnts per one mowe by the Ficull method. Values are mean 
+ SD. The 2 week old noninfeclcd group (n = 31’ peripherrtl blood, B = 26.9 ? 4.5: Thy I 2’ = 56.5 f S.0: Lyt I’. 23’ = 31.3 2 6.1; Lyt I’. ?3- = 23.4 2 
10.1: Lyt I+. 23- = IO.1 ? 6.0: Lyt I-, ?3+ = 5.3 + 5.3: L3T4 = 33.! + 11.11: total lymphwyte count? I x10’) = 3.0 +_ 0.5. Ribavirin-treated noninfected group 
(n = 3): peripheral bM, El = 20.7 2 3.?:Thy I.?’ = 49.9 t 4.7: Lyt I +. 23’ = 31.U r 6.U: Lyl I ‘. 3 = 16.4 + 4.6: Lyt I , ?3+ = 2.4 * 0.8: L3T4’ = 39.4 
f 8.6; Iota1 lymphocyte counts 1* lo”) = I.6 ? 8.6. Spleen. B = 42.7 2 3.5: Thy I.!’ = 39.6 2 7.6. Lyl I +. 13’ = 26.1 t 4.2: Lyt I ‘. 23 = 8.9 ? 5.4: L}t 
I-. 23+ = 4.1 + 2.9: L3TJ+ = 31.7 *_ 9.4 lotal lymphocyte counl~ tx 10’1 = 2.9 2 0.3. 
compared with tbat in control mice, but the difference was 
not statistically significant. Ribavirin inhibited coxsackievi- 
rus B, replication in the heart, and this inhibitory effect 
reflected the decrease of the severity of cardiac pathologic 
changes. 
Lymphwyte behavior in coxsackieviral myccarditis. In 
the acute stage of coxsackievirus B, myocarditis, the data 
suggest a significant involvement of T cell series subsets in 
the development of myocarditis: coxsackievirus B3 affected 
the myocardium in association with a reduction of T cell 
series subsets. in both peripheral blood and spleen in the 
acute stage. The involvement of T cells in the de~~elopment 
of viral myocarditis was also noted in another experimental 
model (16). Reyes and Lerner (6) postulated that, during 
viral infection, sensitized lymphocytes migrate toward the 
target organ (heart), The findings in rlur study explain why 
the severity of myocardids in the coxsackievirus BJ murine 
model is less marked in athymic and nude mice than in mice 
with normal T cett function (4,221. 
Ribavirin primarily inhibited coxsackievirus B, replica- 
tion in the heart. and systematically improved the depletion 
of pan T cells. precursor cells and helper T cells in peripheral 
blood and spleen. Indeed. Gauntt et al. (23) reported that 
BIOLF-70. another antiviral agent, improves rhe depletion 
of a T cell subset (Lyt 2’ marker) in the spleen of mice 
infected uith coxsackievirus B,. In our study, this immuno- 
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logic effect of ribavirin was more marked in the peripheral 
blood than in the spleen, a difference that remains unex- 
plained. 
Murine lymphocyte system. The Lyt 1+,23* subset is the 
possible precrtrsor of the other T cell subsets. in addition to 
the Lyt l-,23+ (suppressorlcytoloxic) subset, Lyt lf,23- 
subsets are not only helper/inducer subsets, but also effec- 
tors of delayed type hypersensitivity (18). L3T4+ cells are 
pure populations of an activated helper subset. 
Cliniral implications. Ribavirirt is; a drug with broad anti- 
viral activity against ribonucleic acid (RNA) and deoxyribo- 
nucleic acid (DNA) viruses (14). Its clinical efficacy has been 
demonstrated in measles (241, influenza (2% respiratory 
syncytial virus infection (26) and Lassa fever (27). More 
recently, ribavirin has been employed for the treatment of 
patients with acquired immunodeficiency syndrome (AIDS) 
and observed to suppress human immunodeficiency virus 
(HIV) in blood and to improve lymphocyte proliferation (28, 
29). However, it may be better to recognize that different 
pathogenic mechanisms may be involved in the development 
of coxsackievirus B3 myocarditis according to the character- 
istics of the host. Huber et al. (30,31) reported that, in 
experimental murine coxsackievirus BJ myocarditis models, 
celltdar immune mechanisms are principal factors in Balblc 
mice (30) and demonstrated the significance of the Lyt 2+ 
subset (31). Humoral immune or autoantibodies against 
heart appear to be a main pathogenic factor in DBAn mice 
(30). In the present study, we used &H/He mice becluse of 
preliminary results showing the severity of cardiac lesions 
and survival curves (32). 
Crmdusions. Ribavirin effectively inhibited myocardial 
coxsackievirus B3 replication and reduced myocardial dam- 
age during acute coxsackievirus B, infection, with improve- 
ment of the depletion of pan T and helper I subsets caused 
by coxsackievirus B, in our experimental preparation. Al- 
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clinical and experimental settings, exploration of clinical 
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where myocardial coxsackievirus B, may exist, appears 
warranted. 
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